Dabigatran Etexilate Mesylate
Kev piav qhia
Dabigatran etexilate mesylate (BIBR 1048MS) yog ib qho tshuaj tiv thaiv kab mob ntawm Dabigatran.Dabigatran etexilate mesylate muaj cov nyhuv anticoagulant thiab siv rau kev tiv thaiv ntawm venousthromboembolism thiab mob stroke vim atrial fibrillation.
Keeb kwm
Nqe lus piav qhia: IC50 Tus Nqi: 4.5nM (Ki);10nM (Thrombin-induced platelet aggregation) [1] Dabigatran yog ib qho kev thim rov qab thiab xaiv, ncaj qha thrombin inhibitor (DTI) tab tom ua tiav kev kho mob siab heev raws li nws qhov ncauj nquag prodrug, dabigatran etexilate.nyob rau hauv vitro: Dabigatran xaiv thiab thim rov qab inhibited tib neeg thrombin (Ki: 4.5 nM) nrog rau thrombin-induced platelet aggregation (IC(50): 10 nM), thaum tsis pom muaj kev cuam tshuam rau lwm cov platelet-stimulating agents.Thrombin tiam hauv platelet. plasma tsis zoo (PPP), ntsuas raws li endogenous thrombin peev xwm (ETP) yog inhibited concentration-dependently (IC(50): 0.56 microM).Dabigatran tau ua kom pom cov nyhuv anticoagulant nyob rau ntau hom hauv vitro, ua ob npaug ntawm lub sijhawm ua haujlwm ib nrab thromboplastin (aPTT), lub sijhawm prothrombin (PT) thiab ecarin clotting lub sij hawm (ECT) hauv tib neeg PPP ntawm qhov ntau ntawm 0.23, 0.83 thiab 0.18 microM, feem. 1].nyob rau hauv vivo: Dabigatran ncua ntev ntawm aPTT koob tshuaj-nyob ntawm seb tom qab txhaj tshuaj hauv cov nas (0.3, 1 thiab 3 mg / kg) thiab rhesus liab (0.15, 0.3 thiab 0.6 mg / kg).Cov koob tshuaj thiab lub sij hawm-dependent anticoagulant tshwm sim tau pom nrog dabigatran etexilate muab qhov ncauj rau cov nas nco qab (10, 20 thiab 50 mg / kg) lossis rhesus liab (1, 2.5 lossis 5 mg / kg), nrog rau qhov siab tshaj plaws tshwm sim ntawm 30 thiab 120 min tom qab kev tswj hwm, feem [1].Cov neeg mob kho nrog dabigatran etexilate tau ntsib tsawg dua ischemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) thiab tsawg dua ua ke intracranial haemorrhages thiab haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) ib tus neeg mob.Kev sim tshuaj: Kev Ntsuas ntawm Pharmacokinetics thiab Pharmacodynamics ntawm Qhov Ncauj Dabigatran Etexilate hauv Hemodialysis Cov Neeg Mob.Theem 1
Cia
| Hmoov | -20 ° C | 3 xyoo |
| 4 ° C | 2 xyoo | |
| Hauv cov kuab tshuaj | -80 ° C | 6 hli |
| -20 ° C | 1 hli |
Kev sim tshuaj
| NCT Num | Txhawb nqa | Qhov xwm txheej | Pib Hnub | Theem |
| NCT02170792 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Ob Hlis 2001 | Theem 1 |
| NCT02170974 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Xya Hli 2004 | Theem 1 |
| NCT02170831 | Boehringer Ingelheim | Noj qab nyob zoo | Tsib Hlis 1999 | Theem 1 |
| NCT02170805 | Boehringer Ingelheim | Noj qab nyob zoo | Plaub Hlis Ntuj 2001 | Theem 1 |
| NCT02170610 | Boehringer Ingelheim | Noj qab nyob zoo | Peb Hlis 2002 | Theem 1 |
| NCT02170909 | Boehringer Ingelheim | Noj qab nyob zoo | Kaum Ob Hlis 2004 | Theem 1 |
| NCT02171000 | Boehringer Ingelheim | Noj qab nyob zoo | Plaub Hlis Ntuj 2005 | Theem 1 |
| NCT02170844 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Rau Hli 2004 | Theem 1 |
| NCT02170584 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Ib Hlis 2001 | Theem 1 |
| NCT02170935 | Boehringer Ingelheim | Venous Thromboembolism | Plaub Hlis Ntuj 2002 | Theem 2 |
| NCT02170636 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Ib Hlis 2002 | Theem 1 |
| NCT02170766 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Kaum Hli 2000 | Theem 1 |
| NCT02171442 | Boehringer Ingelheim | Noj qab nyob zoo | Plaub Hlis Ntuj 2002 | Theem 1 |
| NCT02170896 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Kaum Hli 2001 | Theem 1 |
| NCT02173730 | Boehringer Ingelheim | Noj qab nyob zoo | Kaum Ib Hlis 2002 | Theem 1 |
| NCT02170623 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Ob Hlis 2002 | Theem 1 |
| NCT02170116 | Boehringer Ingelheim | Noj qab nyob zoo | Kaum Ib Hlis 1998 | Theem 1 |
| NCT02170597 | Boehringer Ingelheim | Noj qab nyob zoo | Lub yim hli ntuj 2003 | Theem 1 |
| NCT01225822 | Boehringer Ingelheim | Venous Thromboembolism | Kaum Ib Hlis 2002 | Theem 2 |
| NCT02170701 | Boehringer Ingelheim | Venous Thromboembolism | Lub Kaum Hli 2000 | Theem 2 |
| NCT02170740 | Boehringer Ingelheim | Noj qab nyob zoo | Kaum Ib Hlis 1999 | Theem 1 |
| NCT02170922 | Boehringer Ingelheim | Noj qab nyob zoo | Lub Xya Hli 1999 | Theem 1 |
Cov qauv tshuaj
Tswv yim18Quality Consistency Evaluation tej yaam num uas tau pom zoo4, thiab6tej yaam num raug tso cai.
Advanced thoob ntiaj teb kev tswj hwm qhov system tau tso lub hauv paus ruaj khov rau kev muag khoom.
Kev saib xyuas zoo ua haujlwm los ntawm tag nrho lub neej voj voog ntawm cov khoom kom ntseeg tau tias qhov zoo thiab kho cov nyhuv.
Pab Pawg Kev Tswj Xyuas Kev Tswj Xyuas Kev Ua Haujlwm txhawb nqa qhov kev xav tau zoo thaum lub sijhawm thov thiab tso npe.
Kauslim Countec Lub raj mis ntim kab
Taiwan CVC Lub raj mis ntim kab
Ltalis CAM Board Ntim Kab
German Fette Compacting Tshuab
Nyiv Viswill Tablet Detector
DCS Control Room
